Omada Health, Inc.: insider trades · United States · SEC (Form 4)

About Omada Health, Inc.

Omada Health, Inc. is a U.S.-based digital health company listed on the Nasdaq (OMDA) in the United States. Founded in 2011 and headquartered in San Francisco, California, the company was built around a clear strategic premise: combining virtual care, clinical data, and behavior-change support to improve the long-term management of chronic disease. Its San Francisco location also places it at the center of the U.S. healthcare and technology ecosystem. Omada’s business model is centered on “between-visit” care, meaning services designed to support patients outside traditional office visits. The company offers programs focused on diabetes, diabetes prevention, weight management, hypertension, and broader cardiometabolic health, as well as a musculoskeletal (MSK) program and, more recently, GLP-1 prescribing capabilities. Its offering combines digital tools, member monitoring, health coaching, clinical workflows, and integration with employer, payer, and health-system partners. From an equity research perspective, Omada sits squarely in the enterprise healthtech segment rather than in consumer telemedicine, making its revenue model more closely tied to contracts with organizations than to direct-to-consumer subscriptions. Competitive positioning is driven by several factors. First, Omada has built a clinically oriented platform with evidence-based programs rather than a purely engagement-driven app. Second, it targets large institutional buyers such as employers, health plans, and healthcare systems, which can support scale if retention and outcomes remain strong. Third, the company has long emphasized validation, regulatory recognition, and peer-reviewed outcomes in categories like digital diabetes prevention. In a crowded digital health market, that combination of clinical credibility and enterprise distribution is a meaningful differentiator. Recent developments are important for investors. Omada launched its initial public offering in June 2025 and began trading on the Nasdaq Global Market under the ticker OMDA. The company also reported preliminary 2025 revenue in the range of $256 million to $258 million, implying year-over-year growth of 51% to 52%, ahead of its audited results. In 2026, Omada continued filing SEC reports, including Form 4 insider transaction filings, underscoring its status as a newly public company under active market scrutiny. Overall, Omada is best viewed as a U.S. digital health growth story, exposed to the long-term expansion of chronic care management and virtual-first healthcare delivery, but also to the operational discipline demanded by public markets.